Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401687 | 1.00 | NPSR1 (0.45) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL4781605 | 1.00 | NPSR1 (0.45) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL4780747 | 0.95 | NPSR1 (0.44) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL7619154 | 0.95 | NPSR1 (0.44) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL617286 | 0.82 | NPSR1 (0.48) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL2835654 | 0.82 | NPSR1 (0.48) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 | |
| SCHEMBL1429928 | 0.81 | SMN1; SMN2 (0.63) | NPSR1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL1256350 | 0.81 | SMN1; SMN2 (0.63) | NPSR1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL27175744 | 0.79 | TACR1 (0.41) | ATM | |
| SCHEMBL29240007 | 0.79 | ALDH1A1 (0.42) | NPSR1SMN1; SMN2PKMCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| EP-3331528-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200129496-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10548884-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-3331528-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021728-A9 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017021728-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-02-09 | — | — | WO | disclosed |
| EP-1150969-B1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI SYNTHELABO (FR) | 2002-11-20 | — | — | EP | disclosed |
| EP-0731788-B1 | PROLYL ENDOPEPTIDASE INHIBITORS | MERRELL PHARMA INC (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6413984-B1 | REACTING PYRROLIDINE OR PIPERIDINE ALDEHYDE WITH METAL QUINO-LINE; OPTIONAL DEHYDROXYLATION AND/OR AMINE SUBSTITUTION; MIGRAINES, VASOCONSTRICTION OF NASAL MUCOSA, GASTROINTESTINAL DISORDERS, VEINOUS INSUFFICIENCY | SANOFI-SYNTHELABO (FR) | 2002-07-02 | — | — | US | disclosed |
| EP-1150969-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046219-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | disclosed |
| WO-1998033793-A1 | α-AZACYCLOMETHYL BENZOTHIOPHENE AND α-AZACYCLOMETHYL BENZOFURANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| US-5661167-A | MEMORY ENHANCEMENT, PREVENTING OR SLOWING THE AFFECT OF AMNESIA OR MEMORY DEFICITS | MERRELL PHARMACEUTICALS INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0731788-A1 | PROLYL ENDOPEPTIDASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015310-A1 | PROLYL ENDOPEPTIDASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548884-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | NPSR1 51/4885SMN1; SMN2 2255/4885PKM 2052/4885 |
| US-20200129496-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM4 | NPSR1 51/4885SMN1; SMN2 2177/4885PKM 2071/4885 |
| US-11324738-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | NPSR1 51/4885SMN1; SMN2 2177/4885PKM 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.